PTO/SB/08A (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Unter the Panerwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Page 1 of 6

SERIAL NO. ATTY, DOCKET NO. A TOP 1449APTO SUFFORMATION DISCLOSURE 10/521,008 0253.410US/16384US04 APPLICANT(s): Van Den Hazel, et al. FILING DATE GROUP ART UNIT: (use as many sheets as necessary) 01/03/2005 Not yet assigned

SAME THAN		1	U.S. PATENT	DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	Al	4,457,867	07/03/84	Ishida, T.		T	
	A2	4,588,585	05/13/86	Mark, eat al.		1	
	A3	4,604,284	08/05/86	Kung, et al.			
	A4	4,695,623	09/22/87	Stabinsky, Y.			
	A5	4,727,138	02/23/88	Goeddel, et al.			
	A6	4,758,656	07/19/88	Itoh, et al.			
	A7	4,762,791	08/09/88	Goeddel, et al.			
	A8	4,832,959	05/23/89	Engels, et al.			
	A9	4,835,256	05/30/89	Taniguchi, et al.			
	A10	4,845,196	07/04/89	Cowling, G.J.			
	A11	4,855,238	08/08/89	Gray, et al.			
	A12	4,897,471	01/30/90	Stabinsky, Y.			
	A13	4,898,931	02/06/90	Itoh, et al.			
	A14	4,904,584	02/27/90	Shaw, G.			
	A15	4,921,698	05/01/90	Shirai, et al.			
	A16	4,925,793	05/15/90	Goeddel, et al.			
	A17	4,929,554	05/29/90	Goeddel, et al.			
	A18	4,944,941	07/31/90	Ammann, A.J.			
	A19	4,966,843	10/30/90	McCormick, et al.			
	A20	4,980,455	12/25/90	Sakaguchi, et al.			
	A21	5,004,689	04/02/91	Fiers, et al.			
	A22	5.041.376	08/20/91	Gething, et al.			
	A23	5.096.705	03/17/92	Goeddel, et al.			
	A24	5.109.120	04/28/92	Ueno, et al.			
	A25	5,157,004	11/20/92	Sakaguchi, et al.			
	A26	5,362,490	11/08/94	Kurimoto, et al.			
	A27	5,376,567	12/27/94	McCormick, et al.			
	A28	5,382,657	01/17/95	Karasiewicz, et al.			
	A29	5,518,899	05/21/96	Kurimoto, et al.			
	A30	5,541,293	07/30/96	Stabinsky, Y.			
	A31	5,554,515	09/10/96	Kurimoto, et al.			
	A32	5,574,137	11/12/96	Gray, et al.			
	A33	5,582,824	12/10/96	Goeddel, et al.			
	A34	5,595,888	01/21/97	Gray et al.			

EXAMINER

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kind decodes of USFTO Patent Duments at waw aspts, gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including guthering, preparing, and submitting the completed application form to the USFTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form audior aggretation for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, p.O. Don 1449 Alcadea, April 22131-1450. DN ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

PTO/SB/08A (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	ATTY. DOCKET NO.	SERIAL NO.
Substitute for form 1449A/PTO	0253.410US/16384US04	10/521,008_
INFORMATION DISCLOSURE	APPLICANT(s):	
STATEMENT BY APPLICANT	Van Den Hazel, et al.	
	FILING DATE	GROUP ART UNIT:
(use as many sheets as necessary)	01/03/2005	Not yet assigned

		U.S. PATENT	DOCUMENTS	
A35	5,661,009	08/26/97	Stabinsky, Y.	
A36	5,672,692	09/30/97	Kurimoto, et al.	
A37	5,690,925	11/25/97	Gray, et al.	
A36	5,711,944	01/27/98	Gilbert, et al.	
A39	5,723,121	03/03/98	Takenaga, et al.	
A40	5,738,846	04/14/98	Greenwald, et al.	
A41	5,747,646	05/05/98	Hakimi, et al.	
A42	5,792,834	08/11/98	Hakimi, et al.	
A43	6.042.822	03/28/00	Gilbert, et al.	
A44	6,046,034	04/04/00	Waschutza, et al.	
A45	6,120,762	09/19/00	Johnson, et al.	
A46	6,770,191	06/23/98	Johnson, et al.	

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NO.	PUBLICATI ON DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	Bi	077 670 B1	04/27/83	EP				
	B2	088 540 A2	09/14/83	EP				
	B3	089 676 A2	09/28/83	EP				
	B6	098 110 A2	01/11/84	EP				
	B5	110 044 A1	06/13/84	EP				
	B6	121 157 B1	06/14/89	EP				
	B7	145 174 B1	09/13/89	EP				
	B8	146 354 A2	06/26/85	EP				
	B9	158 198 A1	10/16/85	EP				
	B10	170 917 B1	02/12/86	EP				
	B11	219 781 A2	04/29/87	EP				
	B12	229 108 B1	07/22/87	EP				
	B13	236 987 B1	09/16/87	EP				
	B14	237 019 A2	09/16/87	EP				
	B15	256 424 B1	08/04/87	EP				
	B16	306 870 A2	03/15/89	EP				
	B17	370 205 A2	05/30/90	EP				

EXAMINER

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not clustion is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this flow may in heat communication to applicant. Applicants unique (salton designation counter (spoisons). *See Kinds Codes or USPTO Patent Documents at www.uspro.gov or MPEP 901.04. **. Enter Office that issued the document, by the two-laters code (wIPO Standard ST.3). **Or Paparence patent documents, the indicator of the year of the region Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. **Applicant is to just eacher must be refigable language Translation is attached.**

Applicant so place a cheer arms free it engigin insugary and 138. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.FR. 1.97 and 17.88. The information is retained to take 2 hours to complete, including applicancy, preparing and althoriting the completed applications. Confidentiality is governed by 35 U.S.C. 122 and 37 C.FR. 1.19 and 17.88. The information is estimated to take 2 hours to complete, implication from the USPTO. Time will vary very preparing upon the individual case. Any comments on the amount of time you represent the completed applications from the USPTO. Time will vary very preparing upon the individual case. Any comments on the amount of time you reparable completed applications of the individual case. Any comments on the amount of time you reparable completed applications of the individual case. Any comments on the amount of time you reparable completed applications of the individual case. Any comments on the amount of time you reparable preparable completed applications of the individual case. Any comments on the amount of time you reparable great preparable preparable

[[you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

Rev. Sept. 03

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JS/ 10521008 - GAU: 1647

PTO/SB/08A (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a wait of WB control number.

		Page 3 of 6	
0 h = 12 h = 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4 + 4	ATTY. DOCKET NO.	SERIAL NO.	
Substitute for form 1449A/PTO	0253.410US/16384US04	10/521,008	
INFORMATION DISCLOSURE	APPLICANT(s):		
STATEMENT BY APPLICANT	Van Den Hazel, et al.		
	FILING DATE	GROUP ART UNIT:	
(use as many sheets as necessary)	01/03/2005	Not yet assigned	

	FO	REIGN PATI	ENT DOC	UMENTS	
B18	446 582 B1	09/18/91	EP		
B19	546 099 B1	10/12/94	EP		
B20	593 868 B1	04/15/98	EP		
B21	795 332 A2	09/17/97	EP		
B22	860 442 A1	08/26/98	EP		
B23	92/08737 A1	11/14/91	wo		
B24	92/22310 A1	06/19/92	wo		
B25	99/03887 A1	07/13/98	wo		
B26	99/67291 A2	06/18/99	wo		
B27	01/23006 A1	09/28/00	wo		
B28	01/36001 A2	11/13/00	wo		
B29	2 096 532	05/29/92	CA		

ОТН	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CI	Arakawa, et al., Role of Polycationic c-terminal Portion in the Structure and Activity of Recombinant Human Interferon-y, The Journal of Biological Chemistry, 261(18), June 25, pp. 854-39 (1986).
C2	Arakawa, et al., Structure and Activity of Glycosylated Human Interferon-y, Journal of Interferon Research, 6:687-695 (1986).
C3	Bulleid, et al., Source of heterogeneity in secreted interferon-y, Biochem, J. 268:777-781 (1990).
C4	Cantell, et al., Differential Inactivation of Interferon by a Protease from Human Granulocytes, Journal of Interferon Research 12:177-183 (1992).
C5	Castro, et al., The macroheterogeneity of recombinant human interferon-y produced by Chinese-hamster ovary cells is affected by the protein and lipid content of the culture medium, Biotechnol. Appl. Biochem., 21:87-100 (1995).
C6	Curling, et al., Recombinant human interferon-y, Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture, Biochem. J., 272:333-337 (1990).
C7	Devos, et al., Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells, Nucleic Acids Research, 10(8), 2487-2501, November 08, 1982.
C8	Ealick, et al., Three-Dimensional Structure of Recombinant Human Interferon-y, Science, 252:698-702 (1991).
Cé	Farrar, et al., The Molecular Cell Biology of Interferon-y and its Receptor, Annu. Rev. Immunol. 11:572-611 (1993).
C10	Gray, et al., Structure of the human immune interferon gene, Nature, 298:859-863 (August 1992).

EXAMINER

DATE CONSIDERED:

*EXAMINEE: Initial if reference considered, whether or not citation is in conformance with MPEF 600; Draw line through citation if it not in conformance and not considered. Brotaler copy of this flow with next communication to applicant. Applicant's majne; citation designated number opicions). See Kinds Code of USPTO Patent Documents at vow-vamper, gover bifFF 901.04. *Ener Office that issued its documents, by the rws-letter code (WIFO Standard ST.1). *For Japanese parter documents, the citation of the reign of the relign of the communication of the relign of the communication of the communication of the communication of the document of the document under WIFO Standard ST. 10 if you the opportunes you when the document under WIFO Standard ST. 10 if you the opportune you when the document under WIFO Standard ST. 10 if you the opportune you when the document under WIFO Standard ST. 10 if you the opportune you when the document under WIFO Standard ST. 10 if you the opportune you when the document under WIFO Standard ST. 10 if you the opportune you when the document under WIFO Standard ST. 10 if you the opportune you will not be document under WIFO Standard ST. 10 if you the opportune you will not a standard ST. 10 if you the opportune you will not be document under WIFO Standard ST. 10 if you the opportune you will not be a standard ST. 10 if you the opportune you will not be a standard ST. 10 if you the opportune you will not be a standard ST. 10 if you the opportune you will not be a standard ST. 10 if you will not standard ST. 10 if you wil

The collection of information is required by 3 FCR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 USC. 122 and 37 CFR 1.1 This collection of is estimated to take 2 hours to complete, unleighted preferring preparation is required to take 2 hours to complete, unleighted preparation form to the USFTO. This we'll very depending upon the individual case. Any comments on the amount of time by or require to complete this suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Parten and Trademark Office, P.O. Box 1450 Alexandria, V.A. 2331-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. Sent OFFI Commissioner for Patents, P.O. Box 1450 Alexandria, V.A. 2331-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. Sent OFFI Commissioner for Patents, P.O. Box 1450 Alexandria, V.A. 2331-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. Sent OFFI Commissioner for Patents, P.O. Box 1450 Alexandria, V.A. 2331-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. Sent OFFI Commissioner for Patents, P.O. Box 1450 Alexandria, V.A. 2331-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. Sent OFFI Commissioner for Patents, P.O. Box 1450 Alexandria, V.A. 2331-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. Sent OFFI COMPLETED FORMSTO THIS ADDRESS

[] you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

Rev. Sept. 03

PTOIS/106A (08-03)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMENT
Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a vaid OMS control manual
Page 4 of 6

Substitute for form 1449A/PTO	ATTY. DOCKET NO. 0253.410US/16384US04	SERIAL NO. 10/521,008	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(s): Van Den Hazel, et al.		
	FILING DATE	GROUP ART UNIT:	
(use as many sheets as necessary)	01/03/2005	Not yet assigned	

OTH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C11	Griggs, et al., The N-terminus and C-Terminus of IFN-Y Are Binding Domains for Cloned Soluble IFN-Y Receptor, The Journal of Immunology, 149(2) 517-520 (July 15, 1992).
C12	Gu, et al., Improvement of Interferon-y Sialylation in Chinese Hamster Ovary Cell culture by Feeding of N-Acetylmannosamine, Biotechnology & Bioengineering, 58(6) 642-648 (1998).
C13	Haelewn, et al., Interaction of truncated human interferon y variants with the interferon y receptor: crucial importance of Arg-129, Biochem. I., 324, 591 - 595 (1997).
C14	Harmon, et al., Rapid Monitoring of Site-Specific Glycosylation Microheterogeneity of Recombinant Human Interferon-y, Anal. Chem., 68(9) 1465-1473 (1996).
C19	Hogrefe, et al., Amino Terminus Is Essential to the Structural Integrity of Recombinant Human Interferon- y, The Journal of Biological Chemistry, 264(21) 12179-86 (1989).
C19	Hooker, et al., Constraints on the Transport and Glycosylation of Recombinant IFN-7 in Chinese Hamster Ovary and Insect Cells, Biotechnology & Bioengineering, 63(5) 559-572 (1999).
C12	Hsu, et al., Structure and activity of Recombinant Human Interferon-y Analogs, Journal of Interferon Research, 6:663-670 (1986).
C19	James, et al., N-Glycosylation of Recombinant Human Interferon-γ Produced in Different Animal Expression Systems, Bio/Technology, 13:592-96 (June 13, 1995).
C19	Kita, et al., Characterization of a Polyethylene Glycol Conjugate of Recombinant Human Interferon-y, Drug Design and Delivery, 6:157-167 (1990).
C20	Kontsek, et al., Engineered Acid-Stable Human Interferon Gamma, Cytokine, 12(6) 708-710 (June, 2000).
C21	Landar, et al., Design, Characterization, and Structure of a Biologically Active Single-chain Mutant of Human IFN-Y, J. Mol. Biol., 299:169-179 (2000).
C22	Leinikki, et al., Reduced Receptor Binding by a Human Interferon-, Fragment Lacking 11 Carboxyl- Terminal Amino Acids, Journal of Immunology, 139(10) 3360-3366 (1987).
C23	Littman, et al., Binding of Unglycosylated and Glycosylated Human Recombinant Interferon-y to Cellular Receptors, Journal of Interferon Research, 5: 471-476 (1985).
C24	Lord, et al., Functional Domains of Human Interferon Gamma Probed With Antipeptide Antibodies, Molecular Immunology, 26(7) 637-640 (1989).
C25	Luk, et al., Structure-Function Analysis of the Human Interferon y, The Journal of Biological Chemistry, 265 (22) 13314-13319 (1990).
C26	Lundell, et al., Importance of the Loop connecting A and B Helices of Human Interferon-\(\gamma\) in Recognition by Interferon-\(\gamma\) Receptor*, The Journal of Biological Chemistry, 269(23) 16159-16162.
C27	Lundell, et al., Structural Elements Required for Receptor Recognition of Human Interferon-Gamma, Pharmac. Ther. 64:1-21 (1994).
C28	Lundell, et al., The carboxyl-terminal region of human interferon γ is important for biological activity: mutagenic and NMR analysis, Protein Engineering, 4(3) 335-341 (1991).

EXAMINER

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique cluston designation number (optional). *See Kinds Codes or USPTO Patent Documents at www.spts.gov of the MPEP 901.04. **Enter Office that issued the document, by the two-letter code (WPIO Standard ST.). *To *To Appances patent cohorments, the indicato chorument, but indicato choruments, the indicato choruments are considered. In the property of the patent of the patent of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. *Applicant is to place a check must be in English language Transition is attached.

Applicate as to puted a tender man enter in indigatal anguinger. Institution is antenerous.

This collection of information is required by Y CPR II 79 at 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) as applicates. Confidentiality is governed by YS U.S. C. 122 and 3 fairing in 198. The information of the internal confidence in the public required properties of the information of the infor

Rev. Sept. 03

PTO/SB/08A (08-03) U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Page 5 of 6

Substitute for form 1449A/PTO	ATTY. DOCKET NO. 0253.410US/16384US04	SERIAL NO. 10/521,008	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(s): Van Den Hazel, et al.		
(use as many sheets as necessary)	FILING DATE 01/03/2005	GROUP ART UNIT: Not yet assigned	

OTH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C29	Lunn, et al., A point mutation of human interferon y abolishes receptor recognition, Protein Engineering, 5(3) 253-257 (1992).
C30	Lunn, et al., A point mutation that decreases the thermal stability of human interferon y, Protein Engineering, 5(3) 249-252 (1992).
C38	Mortz, et al., Mass spectrometric characterization of glycosylated interferon-γ variants separated by gel electrophoresis, Electrophoresis, 17:926-931 (1996).
C32	Nishi, et al., Cloning and Expression of a Novel Variant of Human Interferon-y cDNA, J. Biochem, 97 (1) 153-159 (1985).
C33	Nyberg, et al., Metabolic Effects on Recombinant Interferon-γ Glycosylation in Continuous Culture of Chinese Hamster Ovary Cells, Biotechnology & Bioengineering, 62(3) 336-347 (1999).
C34	Oliver, et al., The use of electrospray ionization MS to determine the structure of glycans in intact glycoproteins, Biochem. Mass Spectro., 24:917-927 (1996).
C35	Pan, et al., Structural characterization of human interferon y, FEBS 145-149 (1987).
C36	Rinderknecht, et al., Natural Human Interferon-y, Journal of Biological Chemistry, 259(11) 6790-6797 (1984).
C37	Riske, et al., Characterization of Human Interferon-γ and Human Interleukin-2 from Recombinant Mammalian Cell Lines and Peripheral Blood Lymphocytes, Lymphokine and Cytokine Research, 10 (3) 213-218, (1991).
C38	Sakaguchi, et al., Human interferon-γ lacking 23 COOH-terminal amino acids is biologically active, FEBS Letters, 230(1,2) 201-204 (March 1988).
C39	Sano, et al., Structural Characterization of Recombinant Human Interferon-Gammas Derived from Two Different Mammalian Cells, Microbiol. Immunol., 32 (5) 499-510 (1988).
C40	Sarencva, et al., Biosynthesis and N-glycosylation of human interferon-v Asn25 and Asn97 differ markedly in how efficiently they are glycosylated and in their oligosaccharide composition, Eur. J. Biochem., 142:191-200 (1996).
C41	Sareneva, et al., N-glycosylation of human interferon-y: glycans at Asn-25 are critical for protease resistance, Biochem. J. 308:9-14 (1995).
C42	Sareneva, et al., Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-y, Biochem. J., 303:831-840 (1994).
C43	Sareneva, et al., Effect of Carbohydrates on the Pharmacokinetics of Human Interferon-y, Journal of Interferon Research, 13:267-269 (1993).
C44	Seelig, et al., Evidence for a Polypeptide Segment at the Carboxyl Terminus of Recombinant Human y Interferon Involved in Expression of Biological Activity, Biochemistry, 27(6) 1981-1987 (1988).
C45	Slodowski, et al., Carboxy-terminal truncated rhuIFN-y with a substitution of Gln133 o Ser132 to leucine leads to higher biological activity than in the wild type, Euro. J. Biochem, 202:1133-1140 (1991).

EXAMINER

DATE CONSIDERED:

*EXAMINES: Initial If inference considered, whether or not cliston's is conformance with MPEP 609. Dow line through cliston if on it conformance and not considered. Enclade you of this from what the accommunications is applicant. *Applicant studies cliston's designation number (opinion). *Test Radio (1976 Planta Documents at wow supplica or MPEP 901.04. *Bear Office that issued the document, by the two-letter code (WIPO Standard ST.1). *For Japanese patent document, inclination of the year of the reign of the Engineer must prevent the serial number of the patent document. *Kind of document by the appendix provides a stidiated on the document under WiPO Standard St. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

"Applicable do place 2 check man, here if English imaging Installation a difference in required to obtain or remain a benefit by the public which is to file (not by the USPTO o process) as application. Confidentially is governed by 3 U.S.C. 22 and 37 CFR 1.4.1 This collection is estimated to take 2 bount to emprise, installing states preparing, and orbinniting the completed application. Confidentially is governed by 3 U.S.C. 22 and 37 CFR 1.4.1 This collection is estimated to take 2 bount to emprise, installing states preparing, and orbinniting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form another completed application from the USPTO. The completed application of the USPTO. The STATE of the USPTO FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1800-786-9199) and select option 2.

PTO/SB/08A (08-03) U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Page 6 of 6

Substitute for form 1449A/PTO	ATTY. DOCKET NO. 0253.410US/16384US04 10/521,008 APPLICANT(s): Van Den Hazel, et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)	FILING DATE 01/03/2005	GROUP ART UNIT: Not yet assigned	

OTH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C48	Subramaniam, et al., The Carboxyl Terminus of Interferon-y Contains a Functional Polybasic Nuclear Localization Sequence, Journal of Biological Chemistry, 274(1) 403-407 (1999).
C47	Tang, et al., Studies on the PEGylation of Protein at a Specific Site: Sulfhydryl-PEGylation of 97 Cys- IFN-y, Acta Biochimica et Biophysica Sinica, 28(3) 1-5 (May, 1996).
C48	Taya, et al., Cloning and structure of the human immune interferon-y chromosomal gene, The EMBO Journal, 1(8) 953-958 (1982).
C49	Trousdale, et al., Human Alpha and Gamma Interferon Analogs in Rabbits with Herpetic Keratitis, Invest. Ophth. & Vis. Sci., 26(9) 1244-1251 (1985).
C50	Waschütza, et al., Interferon-yvariants with deletions in the AB surface loop, Eur. J. Biochem., 256:303-309 (1998).
C51	Wetzel, et al., Mutations in Human Interferon Gamma Affecting Inclusion Body Formation Identified by a General Immunochemical Screen, Bio/Technology, 9:731-737 (1991).
C52	Zhang, et al., Quantitative analysis and process monitoring of site-specific glycosylation microheterogeneity in recombinant human interferon-y from Chinese hamster ovary cell culture by hydrophillic interaction chromatography, Journal of Chromatogr. B, 712:73-82 (1998).
C53	Ziesche, et al., A Preliminary Study of Long-Term Treatment with Interferon Gamma-lb and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary Fibrosis, The New England Journal of Medicine, 341(7) 1264-1269 (1999).
C54	Wetzel, et al., Mutational Analysis of the C-terminus of Hyman Interferon-y, Protein Engineering, 3:(7) pp. 611-623 (1990).
C55	Alberts, et al., Molecular Biology of the Cell, 1989.

			_
EXAMINER	/Jegatheesan Seharaseyon/	DATE CONSIDERED: 03/30/2	กกล

*EXAMINER: Intial Inference coasident, whether or not citation is conformance with NEPE 699. Drow less through citation if not in conformance and not considered. Intials copy of this form with next communication to applicac. A "policitaria studies citation designation number of policional." Dee Rand Code of USFTO Patent December 3 was varying over MEPE 991.04. *Eater Office that issued the document, by the two-class code (MEPO Standard ST.1). *For Japanese patent document, end citations of the year of the regin of the Emperor must proceed the serial number of the patent of course by the appropriate personals as in a contract of the patent of course of the patent of the ⁶Applicant is to place a check mark here if English language Translatioo is attached.

"Applicate is to place a check mark here if English language Installation's stricted.

This sollection of information is required by O'CR II 27 and 18.9. The information in required to obtain or remain a breast if by the public which is no life (see My whe USPTO to process). This sollection of information is required to the last 2 hours to exopple, including application, greating and homisting completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form adder suggestions from which the sect to the Chile Information Officer, Oo. Box 1450A Alexandris, Va. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450A Alexandris, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner